Regeneron

FDA clears Dupixent for chronic spontaneous urticaria in patients aged 12 and above, expanding its use in immune-related skin…

Lerodalcibep is a novel therapy designed to lower low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic…

2024 top biotech and pharma employers survey by Science magazine identifies leading companies in the industry

With the growth in AD, investment opportunities seem to be exciting, and pharmaceutical companies could invest in the R&D of…

Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement

The drugs - Regeneron's Inmazeb and Ridgeback Bio's Ebanga- use laboratory-made monoclonal antibodies that mimic natural…

The Food and Drug Administration (FDA) said the treatments are currently not cleared for use in any US states or territories, but…

It is a mixture of three monoclonal antibodies, and the first FDA-approved treatment for Ebola virus infection in adult and…

The agreement, under Operation Warp Speed, is to develop a monoclonal antibody cocktail that can prevent COVID-19, especially in…

Previous trial results had shown that the drug did not help patients with less severe COVID-19, the disease caused by the novel…